enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) (Padcev/Keytruda): FDA status

Under review Indication: Perioperative treatment of cisplatin eligible muscle invasive bladder cancer.

Regulatory history

All products in the FDA Tracker

Loading today's edition…